SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies-Reference-Cited by-同舟云学术

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

Published:2014-07-01 Issue:17 Volume:20 Page:4574-4583
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Deckert Jutta,Wetzel Marie-Cécile,Bartle Laura M.,Skaletskaya Anna,Goldmacher Victor S.,Vallée François,Zhou-Liu Qing,Ferrari Paul,Pouzieux Stéphanie,Lahoute Charlotte,Dumontet Charles,Plesa Adriana,Chiron Marielle,Lejeune Pascale,Chittenden Thomas,Park Peter U.,Blanc Véronique

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 268 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease;Pharmaceuticals;2024-08-05

2. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04

3. Combining CD38 antibody with CD47 blockade is a promising strategy for treating hematologic malignancies expressing CD38;Frontiers in Immunology;2024-06-25

4. Engineered CD147-Deficient THP-1 Impairs Monocytic Myeloid-Derived Suppressor Cell Differentiation but Maintains Antibody-Dependent Cellular Phagocytosis Function for Jurkat T-ALL Cells with Humanized Anti-CD147 Antibody;International Journal of Molecular Sciences;2024-06-16

5. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-06